Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats.
OBJECTIVE
To investigate the protective effect of lansoprazole on ischemia and reperfusion (I/R)-induced rat intestinal mucosal injury in vivo.


METHODS
Intestinal damage was induced by clamping both the superior mesenteric artery and the celiac trunk for 30 min followed by reperfusion in male Sprague-Dawley rats. Lansoprazole was given to rats intraperitoneally 1 h before vascular clamping.


RESULTS
Both the intraluminal hemoglobin and protein levels, as indices of mucosal damage, significantly increased in I/R-groups comparison with those of sham-operation groups. These increases in intraluminal hemoglobin and protein levels were significantly inhibited by the treatment with lansoprazole at a dose of 1 mg/kg. Small intestine exposed to I/R resulted in mucosal inflammation that was characterized by significant increases in thiobarbituric acid-reactive substances (TBARS), tissue-associated myeloperoxidase activity (MPO), and mucosal content of rat cytokine-induced neutrophil chemoattractant-1 (CINC-1). These increases in TBARS, MPO activities and CINC-1 content in the intestinal mucosa after I/R were all inhibited by pretreatment with lansoprazole at a dose of 1 mg/kg. Furthermore, the CINC-1 mRNA expression was increased during intestinal I/R, and this increase in mRNA expression was inhibited by treatment with lansoprazole.


CONCLUSIONS
Lansoprazole inhibits lipid peroxidation and reduces development of intestinal mucosal inflammation induced by I/R in rats, suggesting that lansoprazole may have a therapeutic potential for I/R injury.
Ichikawa
Hiroshi
H
Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
Yoshida
Norimasa
N
Takagi
Tomohisa
T
Tomatsuri
Naoya
N
Katada
Kazuhiro
K
Isozaki
Yutaka
Y
Uchiyama
Kazuhiko
K
Naito
Yuji
Y
Okanoue
Takeshi
T
Yoshikawa
Toshikazu
T
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000517:prevention & control; D007413:Intestinal Mucosa / Q000098:blood supply / Q000187:drug effects / Q000473:pathology*; D007511:Ischemia / Q000517:prevention & control*; D064747:Lansoprazole; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D005765:Gastrointestinal Agents; D064747:Lansoprazole; D009853:Omeprazole